Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KYTX Kyverna Therapeutics

交易中 08-20 11:00:39 EDT

8.17

-0.70

-7.89%

最高8.76	最低8.16	成交量24.35万
今开8.73	昨收8.87	日振幅6.76%
总市值5.05亿	流通市值3.24亿	总股本6,184万
成交额203.32万	换手率0.61%	流通股本3,972万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":8.17,"timestamp":1787238033787,"preClose":8.87,"halted":0,"volume":243520,"delay":0,"changeRate":-0.07891770011273949,"floatShares":39715000,"shares":61843444,"eps":-2.880877,"marketStatus":"交易中","change":-0.7,"latestTime":"08-20 11:00:39 EDT","open":8.73,"high":8.76,"low":8.16,"amount":2033172.832,"amplitude":0.067644,"askPrice":8.18,"askSize":200,"bidPrice":8.16,"bidSize":55,"shortable":3,"etf":0,"ttmEps":-2.880877,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787256000000},"marketStatusCode":2,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.87,"preHourTrading":{"tag":"盘前","latestPrice":8.85,"preClose":8.87,"latestTime":"09:28 EDT","volume":802,"amount":7088.710382,"timestamp":1787232512274,"change":-0.02,"changeRate":-0.002255,"amplitude":0.129651},"postHourTrading":{"tag":"盘后","latestPrice":8.83,"preClose":8.87,"latestTime":"19:30 EDT","volume":6826,"amount":60548.059,"timestamp":1787182207037,"change":-0.04,"changeRate":-0.00451,"amplitude":0.032694},"volumeRatio":1.268582,"impliedVol":0.9949,"impliedVolPercentile":0.243},"requestUrl":"/m/hq/s/KYTX/wiki","defaultTab":"wiki","newsList":[{"id":"1110937187","title":"Kyverna Therapeutics 与 Elevatebio 达成 Miv-Cel 商业生产与供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1110937187","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110937187?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:02","pubTimestamp":1785153775,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics 与 Elevatebio 正式签署了一项针对 Miv-Cel 的商业化生产及供应协议。这一合作标志着双方在细胞治疗领域的战略布局迈出了关键一步，旨在确保 Miv-Cel 能够顺利进入规模化生产阶段，并满足未来市场的潜在需求。通过整合 Elevatebio 的制造专长与 Kyverna 的研发能力，该协议有望加速这一创新疗法的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650634136","title":"纳斯达克生物科技指数一度跌超3%，成分股Kyverna Therapeutics目前跌12.45%，Prime Medi","url":"https://stock-news.laohu8.com/highlight/detail?id=2650634136","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650634136?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:49","pubTimestamp":1783694978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NBI","SIGA","BK4583","MESO","BK4007","KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131729514","title":"Kyverna Therapeutics任命Ritesh Srivastava为首席法律与合规官，强化领导团队以支持商业化阶段转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1131729514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131729514?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:01","pubTimestamp":1782129684,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics已正式任命Ritesh Srivastava担任公司首席法律与合规官。这一关键人事任命旨在显著增强公司的领导层实力，为其向商业化阶段的战略转型提供坚实支撑。Srivastava先生将负责领导公司的整体法律事务、合规体系构建以及企业治理工作，其丰富的专业经验预计将为Kyverna Therapeutics下一阶段的发展带来重要助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198073291","title":"Kyverna Therapeutics在欧洲风湿病学年会上公布Miv-Cel最新数据，显示其对ACPA阳性、难治性类风湿关节炎疾病活动度有显著降低作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1198073291","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198073291?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:01","pubTimestamp":1780488084,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics在欧洲风湿病学大会上公布了其CAR-T细胞疗法候选药物miv-cel的更新数据。数据显示，在接受治疗的抗瓜氨酸蛋白抗体阳性、且对现有疗法反应不佳的难治性类风湿关节炎患者中，该疗法能显著降低疾病活动度。此次公布的数据进一步证实了miv-cel在这一患者群体中的潜力。Kyverna Therapeutics专注于开发用于自身免疫性疾病的工程化T细胞疗法。公司表示，这些积极数据支持了miv-cel的持续临床开发计划，旨在解决严重自身免疫性疾病领域未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160299832","title":"Kyverna Therapeutics任命神经学与罕见疾病领域资深商业领袖Nadia Dac为首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1160299832","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160299832?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896146,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics宣布任命纳迪亚·达克（Nadia Dac）担任首席商务官一职。达克女士在神经学及罕见疾病领域拥有深厚的商业化领导经验，将为公司战略发展注入关键动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162434050","title":"Kyverna Therapeutics股价大涨7.3% 罕见肌肉疾病细胞疗法中期数据表现强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1162434050","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162434050?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:33","pubTimestamp":1776864795,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公司股价今日显著上扬，涨幅达7.3%。这一积极市场反应源于该公司针对罕见肌肉疾病的细胞疗法在中期临床试验中取得了令人鼓舞的成果。\n试验数据显示，该疗法在中期阶段展现出强劲的有效性和可控的安全性特征，为后续研发注入了信心。受此利好消息推动，投资者对该公司前景的乐观情绪明显升温，直接反映在股价的强势表现上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115847455","title":"Kyverna Therapeutics股价盘前飙升21% 中期试验显示其疗法改善僵人综合征患者活动能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1115847455","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115847455?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:20","pubTimestamp":1776853224,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics的股价在盘前交易中大幅上涨21%，此前该公司宣布其针对僵人综合征的疗法在中期临床试验中显示出能够显著改善患者的行动能力。\n这一积极数据提振了投资者信心，推动该公司股价在开盘前出现强劲走势。僵人综合征是一种罕见的神经系统疾病，会导致患者肌肉僵硬和痉挛，严重影响日常活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113314168","title":"Kyverna Therapeutics公布KYSA-8试验主要分析结果：Miv-Cel治疗SPS取得积极成效","url":"https://stock-news.laohu8.com/highlight/detail?id=1113314168","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113314168?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:52","pubTimestamp":1776811935,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics Inc (KYTX) 近日宣布，其针对僵人综合征（SPS）的嵌合抗原受体T细胞疗法Miv-Cel（KYV-101），在名为KYSA-8的临床试验中完成了主要分析。结果显示，该试验达到了预设的主要终点，展现出显著的治疗潜力。\n此次公布的数据进一步验证了Miv-Cel在改善SPS患者临床症状方面的积极效果。公司表示，详细结果将在未来的医学会议上公布，并计划与监管机构讨论后续开发策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148269805","title":"Kyverna Therapeutics公布Miv-Cel治疗全身型重症肌无力二期长期积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1148269805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148269805?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:05","pubTimestamp":1776686742,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics Inc (KYTX) 近日宣布，其针对全身型重症肌无力的候选疗法Miv-Cel在二期临床试验中取得积极长期随访结果。数据显示，该疗法在延长观察期内持续展现出良好的安全性与耐受性特征，同时关键疗效指标维持稳定改善趋势。这一进展为后续关键临床试验的设计与推进提供了重要依据，也增强了业界对该细胞疗法潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187806317","title":"Kyverna Therapeutics：24周时100%患者实现MG-ADL与QMG快速持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1187806317","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187806317?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:03","pubTimestamp":1776686634,"startTime":"0","endTime":"0","summary":"临床数据显示，Kyverna Therapeutics在研疗法取得突破性进展——所有受试患者在24周观察期内均展现出肌无力日常生活活动量表和定量肌力测试评分的快速且持久的改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126929975","title":"Kyverna Therapeutics与Jefferies签订公开市场销售协议 日期为2025年3月27日——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1126929975","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126929975?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:51","pubTimestamp":1775163073,"startTime":"0","endTime":"0","summary":"根据一份日期为2025年3月27日提交至美国证券交易委员会的文件显示，Kyverna Therapeutics Inc已与Jefferies LLC正式签署了一项公开市场销售协议。该协议的签订意味着Kyverna Therapeutics已授权Jefferies作为其销售代理，未来可在公开市场上根据市场条件，按公司指示的价格和数量出售其普通股股份。此次协议的签署，反映了Kyverna Therapeutics在资本运作方面的积极布局，旨在为公司的运营和未来发展提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118984791","title":"Kyverna Therapeutics发布业务进展及2025年第四季度与全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1118984791","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118984791?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:03","pubTimestamp":1774555393,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics（股票代码：KYTX）近日同步披露了公司最新业务动态及2025财年第四季度与全年财务报告。此次公告全面呈现了企业在研发管线推进、战略合作拓展及财务状况方面的关键进展，为投资者评估公司发展轨迹提供了重要依据。通过系统性梳理运营成果与财务数据，Kyverna进一步明确了其在细胞治疗领域的技术布局与商业化路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616322697","title":"Kyverna Therapeutics, Inc.盘中异动 快速跳水5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616322697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616322697?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:48","pubTimestamp":1772549307,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时48分，Kyverna Therapeutics, Inc.股票出现异动，股价大幅下挫5.29%。截至发稿，该股报8.06美元/股，成交量3.4792万股，换手率0.06%，振幅3.52%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.35%。其相关个股中，Edesa Biotech, Inc.、Calcimedica, Inc.、Hcw Biologics Inc.涨幅较大，Adial Pharmaceuticals, Inc、Propanc Biopharma, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为116.76%、58.61%、52.81%，振幅较大的相关个股有Edesa Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Cardio Diagnostics Holdings Inc.，振幅分别为40.79%、27.40%、23.03%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322482797a7e086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322482797a7e086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517394880","title":"Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517394880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517394880?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:41","pubTimestamp":1741185660,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时41分，Kyverna Therapeutics, Inc.股票出现异动，股价急速拉升5.48%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为414.92%、265.37%、199.22%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Tonix Pharmaceuticals Holding Corp.，振幅分别为23.90%、20.71%、19.74%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。其产品KYV-101是一种自体 CD19 CAR T细胞候选产品，由潜在的嵌合抗原受体制成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224100a260cad8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224100a260cad8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KYTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516663055","title":"Kyverna Therapeutics, Inc.盘中异动 股价大跌5.28%报2.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516663055?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:06","pubTimestamp":1741014392,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时06分，Kyverna Therapeutics, Inc.股票出现波动，股价快速跳水5.28%。截至发稿，该股报2.69美元/股，成交量4.8885万股，换手率0.11%，振幅7.04%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1138.48%、126.15%、102.55%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、48.34%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230632a25d4abf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230632a25d4abf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KYTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514763011","title":"Kyverna Therapeutics, Inc.盘中异动 早盘股价大跌5.17%报2.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514763011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514763011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:29","pubTimestamp":1740500969,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时29分，Kyverna Therapeutics, Inc.股票出现波动，股价急速跳水5.17%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Gt Biopharma, Inc.、Silexion Therapeutics Corp、Moleculin Biotech, Inc.较为活跃，换手率分别为1115.47%、909.65%、660.96%，振幅较大的相关个股有Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 、Adial Pharmaceuticals, Inc，振幅分别为87.83%、66.67%、64.05%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600293096300be9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600293096300be9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KYTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514705993","title":"Kyverna Therapeutics, Inc.盘中异动 股价大涨5.04%报2.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514705993?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:47","pubTimestamp":1740430052,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时47分，Kyverna Therapeutics, Inc.股票出现波动，股价大幅上涨5.04%。截至发稿，该股报2.92美元/股，成交量23.5394万股，换手率0.55%，振幅8.57%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.31%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为331.77%、144.98%、41.60%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、164.23%、81.92%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225044732a25262e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225044732a25262e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511452573","title":"Kyverna Therapeutics, Inc.盘中异动 早盘股价大涨5.45%报2.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511452573","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511452573?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:39","pubTimestamp":1739457553,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时39分，Kyverna Therapeutics, Inc.股票出现异动，股价大幅上涨5.45%。截至发稿，该股报2.81美元/股，成交量7694股，换手率0.02%，振幅3.95%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Dominari Holdings Inc.涨幅较大，Tc Biopharm  Plc、Edesa Biotech, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1018.35%、955.48%、163.64%，振幅较大的相关个股有Moleculin Biotech, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、Edesa Biotech, Inc.，振幅分别为56.19%、32.86%、30.10%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502132239139621bde7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502132239139621bde7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507961596","title":"Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升6.04%报3.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507961596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507961596?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:18","pubTimestamp":1738336715,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时18分，Kyverna Therapeutics, Inc.股票出现波动，股价大幅拉升6.04%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.29%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Nls Pharmaceutics Ltd.、Cyclerion Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1773.35%、1633.77%、122.38%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为63.20%、56.30%、46.27%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312318359877654c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312318359877654c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507262163","title":"Kyverna Therapeutics, Inc.盘中异动 股价大涨6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507262163","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507262163?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:33","pubTimestamp":1738247588,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时33分，Kyverna Therapeutics, Inc.股票出现异动，股价快速拉升6.42%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Kazia Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Alterity Therapeutics Limited、Silexion Therapeutics Corp较为活跃，换手率分别为605.75%、125.00%、103.30%，振幅较大的相关个股有Tectonic Therapeutic, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Alterity Therapeutics Limited，振幅分别为21.38%、21.31%、18.28%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013022330896143dae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013022330896143dae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kyvernatx.com","stockEarnings":[{"period":"1week","weight":0.1019},{"period":"1month","weight":0.2251},{"period":"3month","weight":-0.0034},{"period":"6month","weight":0.1549},{"period":"1year","weight":1.6879},{"period":"ytd","weight":-0.0564}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kyverna Therapeutics, Inc.于2018年6月14日以BAIT Therapeutics, Inc.的名义在特拉华州注册成立，并于2019年10月更名为Kyverna Therapeutics, Inc.。该公司是一家以患者为中心的临床阶段生物制药公司，专注于为患有自身免疫性疾病的患者开发细胞疗法。该公司的目标是通过以患者为中心的方法、广阔的平台、治疗免疫疾病的洞察力以及细胞疗法在医学领域成功应用的经验教训，为患有自身免疫性疾病的患者带来改变疾病的治疗益处。","exchange":"NASDAQ","name":"Kyverna Therapeutics","nameEN":"Kyverna Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kyverna Therapeutics,KYTX,Kyverna Therapeutics股票,Kyverna Therapeutics股票老虎,Kyverna Therapeutics股票老虎国际,Kyverna Therapeutics行情,Kyverna Therapeutics股票行情,Kyverna Therapeutics股价,Kyverna Therapeutics股市,Kyverna Therapeutics股票价格,Kyverna Therapeutics股票交易,Kyverna Therapeutics股票购买,Kyverna Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}